PONTE
VEDRA, Fla., June 1, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Cadrenal
or the Company) (Nasdaq: CVKD) a biopharmaceutical company
developing tecarfarin, a late-stage novel oral and reversible
anticoagulant (blood thinner) for certain rare medical conditions,
announced today that the company will participate in investor and
partnering meetings at the BIO International Convention being
held June 5-8, 2023 in Boston.
During the convention, members of the Cadrenal management team
will conduct one-on-one meetings with registered investors and
pharmaceutical companies, showcasing the company's business and
clinical development strategy, recent corporate achievements, and
anticipated milestones.
"Our clinical development pipeline offers the potential to
address the need for prevention of thrombotic and thromboembolic
events (blood clots) that are not adequately addressed by current
treatment options," said Quang Pham,
Chairman, Chief Executive Officer, and Founder of Cadrenal.
"Patients with chronic kidney disease, blood clotting disorders,
and those with implantable medical devices could benefit from a
more stable and readily reversible anticoagulation agent. Our goal
at Cadrenal is to maximize the value of our pipeline for patients.
BIO International Convention provides an ideal venue for such
conversations, and we look forward to actively engaging with
biopharma representatives and investors in attendance."
Meetings with conference attendees can be scheduled through the
BIO One-on-One Partnering system:
https://www.bio.org/events/bio-international-convention/one-one-partneringtm,
or by emailing Cadrenal's corporate contacts using the information
provided at the end of this press release.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding the Company's clinical development pipeline offering the
potential to address the need for the prevention of thrombotic and
thromboembolic events (blood clots) that are not adequately
addressed by current treatment options, patients with chronic
kidney disease, blood clotting disorders and those with implantable
medical devices benefitting from a more stable and readily
reversible anticoagulant agent, maximizing the value of the
Company's pipeline for patients and the Company actively engaging
with biopharma and investors in attendance at the BIO International
Convention. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the Company's ability to
address the need for prevention of thrombotic and thromboembolic
events (blood clots) that are not adequately addressed by current
treatment options, maximize the value of its pipeline and obtain
regulatory approval for the commercialization of tecarfarin or to
comply with ongoing regulatory requirements, the Company's ability
to complete its planned Phase 3 trial on time and achieve desired
results and benefits as expected, and the risk factors described in
the Company's Annual Report on Form 10-K for the year ended
December 31, 2022, and the Company's
subsequent filings with the SEC, including subsequent periodic
reports on Forms 10-Q and 8-K. Any forward-looking statements
contained in this press release speak only as of the date hereof
and, except as required by federal securities laws, Cadrenal
Therapeutics specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner) with orphan drug and Fast
Track designations for the prevention of systemic thromboembolism
(blood clots) of cardiac origin in patients with end-stage kidney
disease, or ESKD, and atrial fibrillation. Tecarfarin is
specifically designed to leverage a different metabolism pathway
than the oldest and most commonly prescribed Vitamin K antagonist
(warfarin) used in the prevention of thrombosis. Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease
(CKD). For more information, please
visit: www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-2023-bio-international-convention-in-boston-301839314.html
SOURCE Cadrenal Therapeutics, Inc.